Stifel Maintains Aerie Pharma (AERI) As Buy; Has Price Objective Of $50.0

Both the stocks sport a Zacks Rank #1 (Strong Buy). The stock now has a consensus rating of “Buy” and an average target price of $46.22.

A number of other equities research analysts also recently weighed in on the company.

Anido said Aerie expects to file the new drug application for Roclatan by the end of 2017. The brokerage firm has raised the Price Target to $ 50 from a previous price target of $40.

Aerie Pharmaceuticals gapped open higher Wednesday, but traded in a range for the majority of the day. They now have a Dollars 44 price target on the stock. Royal Bank Of Canada upped their price target on Aerie Pharmaceuticals from $51.00 to $55.00 and gave the stock an “outperform” rating in a research report on Thursday. They presently have a $50.00 price target on the stock.

The pharmaceutical company’s shares rose in extended Wednesday by over 62 percent within just 30 minutes after the news, up to $34.44 a share from $21.13 at the close.

The move comes after 8 months positive chart setup for the $554.39 million company. Aerie Pharmaceuticals has a 52 week low of $10.82 and a 52 week high of $33.25. Aerie Pharmaceuticals reported actual earnings last quarter of -0.72 which beats the -0.74 consensus estimate, a 2.70% surprise. When calculating EPS anticipates for the current year from sell-side analysts, the Price to current year EPS stands at 38.20%. An electronic copy of the preliminary prospectus supplement and the accompanying prospectus relating to the offering will be available on the website of the Securities and Exchange Commission at www.sec.gov. State Board of Administration of Florida Retirement System now owns 24,578 shares of the company’s stock valued at $433,000 after buying an additional 1,019 shares during the period. BlackRock Advisors LLC raised its position in shares of Aerie Pharmaceuticals by 15.0% in the second quarter. BlackRock Advisors LLC now owns 12,310 shares of the company’s stock valued at $217,000 after buying an additional 1,608 shares in the last quarter. Barclays PLC raised its position in shares of Aerie Pharmaceuticals by 3.4% in the second quarter. Finally, DekaBank Deutsche Girozentrale increased its stake in Aerie Pharmaceuticals by 17.8% in the second quarter. Nevertheless, the market opportunity in glaucoma is big and growing thanks to aging baby boomers, and that makes this stock one worth considering by risk-tolerant investors.

ANIK and ANI Pharmaceuticals, Inc. The Firm is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. In addition, the IOP-lowering effect of the candidate was 1 mmHg to 3 mmHg greater than monotherapy with either Xalatan or Rhopressa.